The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

Panelists briefly touch on ongoing trials of second-line tucatinib combination therapy, including HER2CLIMB-02 and HER2CLIMB-05, in patients with or without brain metastases, and offer their clinical perspective which second-line regimens they typically recommend for their patients with HER2+ mBC.

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.

Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.

Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.

Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.

Comprehensive insight on the optimal sequencing of novel therapies in patients with relapsed/refractory diffuse large B-cell lymphoma.

Krina K. Patel, MD, MSc, discusses the safety profile of idecabtagene vicleucel in a subgroup of patients with high-risk, relapsed/refractory multiple myeloma, as well as findings with soluble BCMA levels from the phase 3 KarMMa-3 trial.

Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Expert gynecologic oncologists react to data from the MIRASOL trial, which studied mirvetuximab in patients with platinum-resistant ovarian cancer.

Drs McArthur and Kaklamani expand upon the standard-of care regimens used for first-line treatment of patients with HER2+ metastatic breast cancer (mBC), review clinical data supporting their use, and share excitement for upcoming data readouts on novel regimens in the space.

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

A panel of experts on ovarian cancer review ongoing trials on maintenance therapies for recurrent ovarian cancer.

Senthil Damodaran, MD, PhD, discusses the rationale for the phase 3 ELAINE-3 trial in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Shared insight from key opinion leaders in diffuse large B-cell lymphoma on the role of bispecific therapy in the relapsed/refractory space.

A brief review of what one can expect while managing a patient with relapsed/refractory diffuse large B-cell lymphoma on CAR T-cell therapy.

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Panelists discuss recent data updates on standard-of-care and emerging regimens for adjuvant treatment of HER2+ eBC, including data presented at the 2023 ASCO meeting, and highlight exciting trials in progress that have not yet read out.

A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

Ovarian cancer experts review clinical trial data on the efficacy of later-line therapies in advanced ovarian cancer.

Drs Tripathy and McArthur touch on the use of extended adjuvant therapy with neratinib and identify patients who might be suitable for this regimen, including those high-risk patients with residual disease after neoadjuvant therapy.

Treatment with ASP-1929 in combination with pembrolizumab led to responses and was well tolerated in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Focused discussion on treatment guidelines and recommendations for fertility preservation while treating premenopausal patients with breast cancer.

A brief review of monitoring, response assessment, and treatment modification strategies used for patients with breast cancer undergoing OFS. .

Moving into their last module, expert panelists consider how they might inform best selection and sequencing of therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Following their discussion on axicabtagene ciloleucel and lisocabtagene maraleucel, panelists reflect on the real-world use of CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.